Roche hemophilia drug lowers costs despite high price: ICER

(Reuters) – A costly new Roche Holding AG drug to treat the bleeding disorder hemophilia A could significantly reduce healthcare expenses for certain patients, a draft report from an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.